UroGen Pharma
URGN
60 hedge funds and large institutions have $482M invested in UroGen Pharma in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
40% more funds holding
Funds holding: 43 → 60 (+17)
6% more capital invested
Capital invested by funds: $454M → $482M (+$28.4M)
2.03% more ownership
Funds ownership: 60.04% → 62.07% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$26.4M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$19.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.9M |
| 4 |
BlackRock
New York
|
+$5.23M |
| 5 |
WCM
Wildcat Capital Management
New York
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20M |
| 2 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$17.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.18M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.53M |
| 5 |
DP
DSAM Partners
London,
United Kingdom
|
-$3.88M |
URGN Hedge Fund Activity: Q2 2018 in Review
60 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2018, worth a combined $482M — up 6.3% from $454M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new URGN positions and 6 closed out — a net gain of 17 holders — while 21 added to existing stakes and 12 trimmed.
The largest buyer was Menora Mivtachim Holdings, adding an estimated $26.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $20M sold.
- 60 institutional investors held UroGen Pharma (URGN) as of Q2 2018, up from 43 in Q1 2018.
- Funds reported $482M of UroGen Pharma stock for Q2 2018, up 6.3% quarter-over-quarter.
- 23 funds opened new UroGen Pharma positions in Q2 2018 and 6 closed out, a net change of +17 holders.
- The largest UroGen Pharma buyer in Q2 2018 was Menora Mivtachim Holdings, an estimated $26.4M added.
- The largest UroGen Pharma seller in Q2 2018 was EcoR1 Capital, an estimated $20M sold.
Based on aggregated 13F filings for Q2 2018.